----
Current ValuationThe current P/E ratio is -5.93, within the reasonable range, cheaper than 63.7% of the time in the past 5 years, and the industry ranks 29/39, the industry Median -0.80.
-5.93xP/E
$5.79Stock price
$-0.98Earnings per share
-5.93xP/E
Stock price$5.79Earnings per share$-0.98
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -1.66x
- Typical range
- -8.18x–-0.67x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
012243648
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
HTFLUSHeartFlow | -38.35x | 76.19% | $4.54B |
SDGRUSSchrodinger | -44.88x | 13.66% | $2.44B |
CERTUSCertara | -22.46x | 1,962.60% | $1.54B |
TDOCUSTeladoc | -5.93x | 22.88% | $1.05B |
MDRXUSVeradigm | -- | -- | $851.43M |
SOPHUSSophia Genetics SA | -8.63x | 19.83% | $698.05M |
CTEVUSClaritev | -1.48x | 12.62% | $418.26M |
EVHUSEvolent Health | -0.80x | 84.41% | $408.14M |
AMWLUSAmerican Well | -2.77x | 57.74% | $216.35M |
DHUSDefinitive Healthcare | -0.85x | 28.60% | $142.84M |
HCATUSHealth Catalyst | -0.50x | 4.22% | $132.45M |
LFMDUSLifeMD | -45.13x | 195.82% | $131.11M |
DRIOUSDarioHealth | -8.12x | 62.43% | $56.80M |
RNLXYUSRENALYTIX PLC SPON ADS EACH REP 50 ORD (POST SPLIT) | -2.26x | -- | $44.93M |
ONMDUSOneMedNet | -3.60x | -- | $30.30M |
ITOCUSiTonic | -3.33x | -- | $29.68M |
AIFFUSFirefly Neuroscience | -2.16x | -- | $20.40M |
BFRGUSBullfrog AI | -1.84x | 41.27% | $11.01M |
HCTIUSHealthcare Triangle | -0.53x | 93.28% | $9.09M |
ACONUSAclarion | -0.73x | 65.17% | $6.74M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
